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Hypomagnesemia and hypocalcemia are common adverse
events during cetuximab treatment. The influence
of the chemotherapeutic combination on serum levels
is unknown and the predictive value is currently under
discussion. This analysis investigated 79 patients who
had received cetuximab for at least 6 weeks in the day
clinic of the Comprehensive Cancer Center, University
of Munich. Calcium and magnesium serum levels were
analyzed weekly; tumor response and adverse events
were followed. Thirty-eight patients had metastatic
colorectal cancer (mCRC) and the predictive value of
hypomagnesemia was tested in these patients. During
therapy, calcium serum levels decreased to about 97%
of the baseline levels and were maintained for the duration
of treatment. Magnesium levels showed a significant
time-dependent decrease. Serum levels of magnesium
were lower when cetuximab was combined with a platinum
derivative. After a treatment duration of 12 weeks,
magnesium levels decreased to 70% in platinum-treated
patients, whereas they decreased to only 90% of baseline
in patients who did not receive platinum therapy. In patients
treated for mCRC, a decrease of serum magnesium below
95% of the baseline levels 14 days after initiating treatment
separated patients significantly in terms of survival times.
Magnesium levels decrease in a time-dependent manner
during cetuximab therapy. As hypomagnesemia was
more prominent in patients receiving platinum agents,
magnesium measurements may be advised in these
patients. In mCRC patients treated with cetuximab, day-14
magnesium serum levels correlated with treatment
efficacy. Anti-Cancer Drugs 24:969–974 c 2013 Wolters
Kluwer Health | Lippincott Williams & Wilkins.
Anti-Cancer Drugs 2013, 24:969–974
Keywords: cetuximab, colon cancer, hypomagnesemia, magnesium,
oxaliplatin
aDepartment of Internal Medicine III and Comprehensive Cancer Center, Klinikum
Grosshadern and bInstitute of Medical Informatics, Biometry and Epidemiology,
University of Munich, Munich, Germany
Correspondence to Sebastian Stintzing, Department of Internal Medicine III
and Comprehensive Cancer Center, Klinikum Grosshadern, University of Munich,
Marchioninistrasse 15, 81377 Munich, Germany
Tel: + 49 89 7095 2208; fax: + 49 89 7095 5256;
e-mail: sebastian.stintzing@med.uni-muenchen.de
Received 12 March 2013 Revised form accepted 10 June 2013
Introduction
Treatment with antibodies directed against the epidermal
growth factor receptor (EGFR) has improved antitumor
treatment efficacy in several entities. Next to the treat-
ment of mCRC [1–3], the anti-EGFR-antibody cetuximab
is approved for the treatment of squamous cell cancer of
the head and neck [4], and was also evaluated in other
malignancies such as lung cancer and gastric cancer [5,6].
The occurrence of hypomagnesemia as a side effect of
cetuximab treatment has been observed within the first
trials using cetuximab [7] and appears to be a class effect of
anti-EGFR antibodies [8]. The mechanism of hypomagne-
semia in anti-EGFR treated patients has been explained by
the link between TRMP6 (transient receptor potential
member 6) and EGFR signaling. Magnesium is absorbed in
the gut and reabsorbed in the ascending loop of Henle by
TRMP6 [9], an ion channel. TRMP6 activation is
mediated by EGFR signaling [10].
Next to acneiform exanthema [11], hypomagnesemia [12]
has also been described as a possible clinical predictor for
outcome. However, conflicting data were reported in
a recent report, indicating that hypomagnesemia induced
by cetuximab monotherapy was associated with inferior
survival [13]. Therefore, the predictive value of magnesium
and calcium decrease is currently under discussion. The
effect of the chemotherapeutic drugs used in combination
with cetuximab on the occurrence and frequency of
hypomagnesemia has not been elucidated. Furthermore,
risk factors defining patients who are more likely to develop
hypomagnesemia have not yet been identified.
The present analysis aimed to define the course of
magnesium and calcium serum levels during cetuximab
exposure and searched for risk factors predicting the
development of hypomagnesemia and hypocalcemia. In
this context, specific focus was on the effect of different
chemotherapy backbones on the development of hypo-
magnesemia and hypocalcemia.
Patients and methods
Patients receiving cetuximab for cancer treatment in the
day clinic of the Comprehensive Cancer Center LMU,
Klinikum der Universität, University of Munich, were
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investigated. In this retrospective analysis, patients
treated from 2009 to 2011 were included. Cetuximab
was administered according to the manufacturer’s in-
structions. After a loading dose of 400 mg/m2 (120 min
intravenously), cetuximab was administered weekly at a
dose of 250 mg/m2 (90–30 min intravenously). Concomi-
tant medication with dimethindene (4 mg intravenously)
and dexamethasone (4 mg intravenously) was adminis-
tered at all treatment cycles. In addition, patients
receiving oxaliplatin for colorectal cancer treatment were
premedicated with calcium gluconate (1 g intravenously)
and magnesium sulfate (1 g intravenously) as prophylaxis
for peripheral neuropathy. In evaluable patients, duration
of cetuximab exposure of at least 6 weeks was required.
To limit the number of parameters included in this
analysis and possibly weakening our conclusions, patients
treated with panitumumab were excluded from this
study.
Clinical parameters
Before each treatment, standard laboratory tests, includ-
ing serum creatinine, glomerular filtration rate (GFR)
calculated using the Cockroft–Gault formula, magnesium,
and calcium, were carried out. Toxicity was evaluated by
a standardized toxicity form, including acneiform exanthema,
skin and nail changes, and diarrhea as cetuximab-specific
parameters. Grading was performed according to NCI
CTC AE version 3.0 (National Institutes of Health,
Bethesda, Maryland, USA). Also, basic patient character-
istics (age, sex, tumor type, KRAS mutational status,
chemotherapeutic regimen, and treatment line) were
determined. Treatment efficacy was defined by best
overall response (RECIST 1.0) and survival times
(progression-free survival and overall survival). The
Ethics Committee of the University of Munich (Gros-
shadern) approved the study design (#081-13).
Statistical analyses
Logistic regression exploration was carried out for
univariate and multivariate analyses to evaluate the
influence of baseline characteristics (age, sex, KRAS
status, serum creatinine, GFR, tumor type, chemother-
apeutic drugs) on changes in the calcium and magnesium
serum levels. To define cut-off levels for decrease in
magnesium, a receiver-operator characteristics (ROC)
curve was constructed and the cut-off was set where the
sum of specificity and sensitivity reached its maximum.
To calculate differences in response, Fisher’s exact test
was used. For differences in survival, Kaplan–Meier
estimates and log-rank P were calculated. To evaluate
the time-dependent manner of magnesium and calcium
levels, analysis of variance testing for repeated measure-
ments was carried out.
All statistical tests were two-sided and a P-value of less
than 0.05 was considered statistically significant.
R (version 2.11.1; R Foundation, Vienna, Austria) and
SPSS PASW 20.0 (SPSS Inc., Chicago, Illinois, USA)
software were used for all statistical analyses.
Results
A total of 97 patients received cetuximab during the
period from 2009 to 2011. Of these, 79 received
cetuximab for a period of at least 6 weeks and therefore
were included in this analysis (for baseline
characteristics, Table 1a). For each parameter (magne-
sium and calcium), 1359 serum measurements were
available for analysis. The toxicities of interest (hypo-
magnesemia, hypocalcemia, acneiform exanthema) were
as presented in Table 1b and c. In brief, a total of nine
patients (11.4%) developed hypomagnesemia reaching
NCI CTC grade 3–4 and six patients (7.6%) developed a
grade 3–4 hypocalcemia. By plotting the mean magne-
sium and calcium levels over time in relation to the
baseline measurements (Fig. 1), two differences could be
observed. Calcium levels decreased nonsignificantly
during the first 2 weeks to a level of about 95–97% of
baseline and were maintained for the entire duration of
treatment. Therefore, calcium levels did not seem to be a
valuable parameter to correlate with treatment efficacy.
In comparison, magnesium levels decreased significantly
(Greenhouse–Geisser P = 0.03) in a time-dependent
manner without reaching a minimum. Furthermore, a
difference could be observed between the magnesium
levels in patients treated with any platinum derivative
and cetuximab and those who received platinum-free chemo-
therapy. In patients treated with platinum derivatives,
the decrease in magnesium was faster and reached lower
levels (about 70% of baseline) than in patients not
treated with a platinum derivative, in whom levels
reached 85–90% of baseline after a treatment duration
of 12 weeks. Using repeated-measures analysis of variance
testing, the difference between platinum and nonplati-
num patients in terms of the course of magnesium did
not differ significantly (Greenhouse–Geisser P = 0.24),
but showed a trend towards lower levels in platinum-
treated patients.
Using Kendall-tau-b rank testing, the occurrence of
acneiform exanthema correlated significantly with the
decrease of serum magnesium levels (correlation coeffi-
cient – 0.21; P = 0.037).
Univariate and multivariate analyses did not show any
association with baseline characteristics and magnesium
levels after 2 weeks of treatment (Table 2). With respect
to calcium levels, the baseline serum creatinine level was
found to be an independent factor for lower calcium
levels in univariate [odds ratio (OR) = 0.61; P = 0.03]
and multivariate (OR = 0.37; P = 0.006) analyses
(Table 3).
For the subgroup of patients with mCRC, representing
the largest subgroup in our analysis, logistic regression
analysis indicated that lower magnesium levels at day 14
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were significantly associated with higher overall response
rates (ORR) (OR = 1.52; P = 0.03). A similar trend was
observed for disease control rate but did not reach
significance (OR = 1.34; P = 0.08). Calcium was not asso-
ciated with either ORR or disease control rate (Table 4).
On constructing ROC curves for response in mCRC
patients, the area under the curve reached 0.625 and the
sum of specificity and sensitivity reached its maximum at
a decrease of magnesium on day 14 of cetuximab
treatment to 95% of the baseline value.
Using this discrimination, patients with lower magnesium
levels had a significantly longer progression-free survival
(4.6 vs. 2.5 months; log-rank P = 0.03; hazard ratio 0.42)
and a trend toward longer overall survival (20.0 vs. 4.4
months, log-rank P = 0.12; hazard ratio 0.45) (Fig. 2). ORR
was doubled in patients with lower magnesium levels on
day 14, but the difference (33.3 vs. 66.7%) did not reach
the level of significance (Fisher’s exact P = 0.053).
Discussion
Hypomagnesemia has been noted as an adverse event
already after the first trials investigating cetuximab [7,14].
Magnesium wasting is supposedly caused by an inhibitory
effect of anti-EGFR agents on TRMP6, which is
responsible for reabsorption of magnesium in the
ascending limp of the loop of Henle [7,9,15]. In most
patients, hypomagnesemia remains asymptomatic and
does not lead to clinical symptoms such as muscle
cramps, fatigue, or general weakness [14]. Therefore,
Table 1 Baseline characteristics and toxicities of interest for cetuximab
n (%)
mCRC (n = 38) SCCHN (n = 27) Othera (n = 14) Total (n = 79)
(a) Baseline characteristics
Age (years) (range) 63.3 (35.3–84.2) 62.4 (46.4–86.2) 68.7 (27.9–84.0) 62.2 (27.9–86.2)
Sex
Male 30 (78.9) 21 (77.8) 9 (64.3) 60 (75.9)
Female 8 (21.1) 6 (22.2) 5 (35.7) 19 (24.1)
KRAS status
Wild-type 27 (71.1) 3 (11.1) 7 (50.0) 37 (46.8)
Mutated 7 (18.4) 0 1 (7.1) 8 (10.1)
Not known 4 (10.5) 24 (88.9) 6 (42.9) 34 (43.1)
Combination partner
Platinum 3 (7.9) 13 (48.1) 7 (50.0) 23 (29.1)
Nonplatinum 35 (92.1) 14 (51.9) 7 (50.0) 56 (70.9)
Therapy line
First line 14 (36.8) 15 (55.6) 5 (35.7) 34 (43.0)
Further line 24 (63.2) 12 (44.4) 9 (64.3) 45 (56.9)
(b) Toxicity (NCI CTC AE version 3.0) by cancer type
Hypomagnesemia
Grade 0 21 (55.3) 13 (48.1) 6 (42.9) 40 (50.6)
Grade 1 11 (28.9) 6 (22.2) 3 (21.4) 20 (25.3)
Grade 2 2 (5.3) 6 (22.2) 2 (14.3) 10 (12.7)
Grade 3/4 4 (10.5) 2 (7.4) 3 (21.4) 9 (11.4)
Hypocalcemia
Grade 0 27 (71.1) 22 (81.5) 7 (50.0) 56 (70.9)
Grade 1 8 (21.1) 2 (7.4) 1 (7.1) 11 (13.9)
Grade 2 2 (5.3) 1 (3.7) 3 (21.4) 6 (7.6)
Grade 3/4 1 (2.6) 2 (7.4) 3 (21.4) 6 (7.6)
Acneiform exanthema
Grade 0–1 7 (18.4) 8 (29.6) 6 (42.9) 21 (26.6)
Grade 2–4 29 (76.3) 17 (62.9) 8 (57.1) 54 (68.4)
Unknown 2 (5.3) 2 (7.4) 0 4 (5.1)
Nonplatinum-containing regimen (n = 56) Platinum-containing regimen (n = 23) Total (n = 79)
(c) Toxicity (NCI CTC AE version 3.0) by platinum-based chemotherapy
Hypomagnesemia
Grade 0 33 (58.9) 7 (30.4) 40 (50.6)
Grade 1 13 (23.2) 7 (30.4) 20 (25.3)
Grade 2 6 (10.7) 4 (17.4) 10 (12.7)
Grade 3/4 4 (7.2) 5 (21.7) 9 (11.4)
Hypocalcemia
Grade 0 41 (73.2) 15 (65.2) 56 (70.9)
Grade 1 11 (19.6) 0 11 (13.9)
Grade 2 2 (13.6) 4 (17.4) 6 (7.6)
Grade 3/4 2 (13.6) 4 (17.4) 6 (7.6)
Acneiform exanthema
Grade 0–1 11 (19.6) 10 (43.5) 21 (26.6)
Grade 2–4 42 (75.0) 12 (52.2) 54 (68.4)
Unknown 3 (5.4) 1 (4.3) 4 (5.1)
mCRC, metastatic colorectal cancer; SCCHN, squamous cell cancer of the head and neck.
aOther refers to: four undifferentiated adenoid tumors of the head and neck, three carcinomas of unknown primary (CUP) with adenoid differentiation, two gastric
cancers, one of each: adenocarcinoma of the lung, breast cancer, prostate cancer.
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magnesium serum levels have only been followed in a
small fraction of patients participating in clinical
trials [1,4,8]. Early changes in magnesium levels have
been described recently as a surrogate parameter for
treatment efficacy in the third-line treatment of
mCRC [12] with irinotecan and cetuximab. Another
study reported a negative prognostic effect when
cetuximab was provided as monotherapy [13] in heavily
pretreated patients.
Even the present analysis has some limitations because
of its retrospective nature and possible selection bias
as patients treated for less than 6 weeks were excluded;
this indicates a time-dependent, significant decrease in
magnesium serum levels in patients treated with
cetuximab. Using baseline characteristics for a logistic
regression analysis, no risk factor could be established for
the decrease in magnesium (Table 2). Risk factors,
therefore, may be found in genetic analyses, but to date,
no known factor to predict hypomagnesemia has been
established from clinical baseline parameters.
Hypocalcemia is a rare event in cetuximab-treated
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Course of calcium and magnesium during cetuximab treatment.
Table 2 Univariate and multivariate logistic regression analysis of baseline factors to predict magnesium decrease on day 14
OR (univariate) (95% CI) P OR (multivariate) (95% CI) P
Age (continuous) (years) 1.01 (0.99–1.02) 0.30 1.00 (0.99–1.02) 0.68
Sex (female) 1.18 (0.86–1.62) 0.17 1.29 (0.82–2.02) 0.27
SCCHN (mCRC as standard) 1.22 (0.93–1.60) 0.17 1.12 (0.76–1.65) 0.56
Other tumor (mCRC as standard) 0.85 (0.58–1.25) 0.41 0.89 (0.57–1.41) 0.63
Platinum 0.93 (0.70–1.23) 0.60 0.85 (0.58–1.25) 0.42
Creatinine (log) (continuous) 1.09 (0.68–1.75) 0.72 0.60 (0.27–1.31) 0.20
GFR (log) (continuous) 0.44 (0.13–1.47) 0.19 0.31 (0.06–1.64) 0.17
KRAS mutation 1.07 (0.94–1.22) 0.34 1.05 (0.87–1.27) 0.63
CI, confidence interval; GFR, glomerular filtration rate; log, logarithmic values; mCRC, metastatic colorectal cancer; OR, odds ratio; P, logistic regression analysis P;
SCCHN, squamous cell cancer of the head and neck.
Table 3 Univariate and multivariate logistic regression analyses of baseline factors to predict calcium decrease on day 14
OR (univariate) (95% CI) P OR (multivariate) (95% CI) P
Age (continuous) (years) 1.00 (1.00–1.01) 0.29 1.01 (1.00–1.02) 0.12
Sex (female) 1.04 (0.80–1.35) 0.80 1.43 (0.96–1.88) 0.09
SCCHN (mCRC as standard) 1.03 (0.81–1.34) 0.74 0.78 (0.62–1.22) 0.41
Other tumor mCRC as standard) 0.86 (0.63–1.17) 0.33 0.78 (0.57–1.08) 0.14
Platinum 0.97 (0.76–1.24) 0.81 1.02 (0.75–1.37) 0.93
Creatinine (log) (continuous) 0.61 (0.40–0.94) 0.03a 0.37 (0.19–0.73) 0.006a
GFR (log) (continuous) 2.66 (0.82–8.62) 0.11 0.85 (0.19–3.90) 0.83
KRAS mutation 1.04 (0.93–1.18) 0.48 1.06 (0.91–1.24) 0.46
CI, confidence interval; log, logarithmic values; mCRC, metastatic colorectal cancer; OR, odds ratio; P, logistic regression analysis P; SCCHN, squamous cell cancer
of the head and neck; GFR, glomerular filtration rate.
aStatistical significant data are given in bold.
Table 4 Correlation of changes of calcium and magnesium (baseline vs. day 14) with parameters of treatment efficacy
mCRC (n = 38) (95% CI) P Database (n = 79) (95% CI) P
ORR
Magnesium (day 14) 1.52 (1.07–2.15) 0.03a 1.15 (0.89–1.50) 0.30
Calcium (day 14) 0.95 (0.68–1.32) 0.74 0.88 (0.71–1.11) 0.30
DCR
Magnesium (day 14) 1.34 (0.98–1.84) 0.08 0.94 (0.74–1.20) 0.64
Calcium (day 14) 0.90 (0.68–1.18) 0.44 0.88 (0.71–1.08) 0.23
CI, confidence interval; DCR, disease control rate; mCRC, metastatic colorectal cancer; ORR, overall response rate; P, Fisher’s exact test P.
aStatistical significant data are given in bold.
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levels are because of changes induced by cetuximab or
secondary to changes in the kidney [17]. The phenom-
enon of hypomagnesemic hypocalcemia is well
known [18] and may therefore contribute to the
hypocalcemia in cetuximab-treated patients. Hypocalce-
mia may further be associated with a preexisting
impairment of renal function. In univariate and multi-
variate logistic regression analyses, baseline serum
creatinine levels were found to be predictive for
hypocalcemia. This indicates that a closer follow-up
should be performed of patients with borderline serum
creatinine levels for hypocalcemia when treated with
cetuximab.
The incidence of grade 3–4 hypomagnesemia in this
cohort was 11%, which is somewhat higher than that
reported before (3–5%) [7,14]. This may be attributed to
the study design as only patients who had received
cetuximab for at least 6 weeks were included and because
magnesium levels decrease in a time-dependent man-
ner [19]. Hypomagnesemia of any grade could be
detected in 49.6% of patients. This rate is higher than
that reported by Petrelli et al. [8], but it is within the
range of another report in which all-grade hypomagnese-
mia was observed in 56% of patients [16]. The discordant
findings may indicate that the lack of routine magnesium
determinations is likely to result in an underestimation of
the frequency and severity of hypomagnesemia during
cetuximab exposure.
The present analysis suggests that patients treated with
cetuximab plus platinum derivatives show a faster
decrease in magnesium levels that results in markedly
lower serum concentrations of magnesium (about 70% of
baseline) compared with patients receiving cetuximab
with other combinations. This platinum-related differ-
ence in the pattern of magnesium kinetics has not been
described before. Previous studies carried out in mCRC
comparing oxaliplatin-based regimens with irinotecan-
based regimen [20,21] did not compare the frequency or
the grade of hypomagnesemia. It may only be speculated
that this was in part because of the insignificant effect of
hypomagnesemia on clinical symptoms and adverse
events.
Recently published analyses recommend routine magne-
sium measurements for all patients treated with cetux-
imab [19]. In the present study, it is shown that
specifically patients treated with cetuximab plus plati-
num derivatives should be monitored for clinical symp-
toms of hypomagnesemia. The reason for the more severe
hypomagnesemia in the platinum plus cetuximab-treated
cohort may be platinum-induced nephrotoxicity, which is
more severe with cisplatin [22], but has also been
reported in oxaliplatin-treated patients [23]. If unusual
fatigue or muscle weakness or cramps occur and
magnesium levels are low, a discontinuation of cetuximab
and intravenous magnesium substitution should be
considered [7].
As mentioned before, the predictive value of the early
decrease in magnesium serum levels is currently under
discussion [12,13]. Using ROC analysis, this analysis
showed that a decrease in magnesium levels lower than
95% of baseline on day 14 of cetuximab exposure is
associated with prolonged survival times in mCRC
patients. Although data of Vincenzi et al. [12] could be
confirmed, the results are in contrast to the report by
Vickers et al. [13]. This may in part be explained by the
different inclusion criteria and regimens used in the
studies. In the present analysis, first-line and second-line
patients were treated with cetuximab in combination
with chemotherapy, which is similar to the more
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were treated with irinotecan and cetuximab as the third-
line treatment. However, patients in the report by Vickers
et al. [13] were heavily pretreated and received cetuximab
as a monotherapy. Detailed data on patients receiving
first-line therapy are still missing. A prospective clinical
trial with a closer follow-up of magnesium serum levels to
validate the retrospective analyses is clearly required
to obtain more information on this issue.
Conclusion
Hypocalcemia is a rare event in cetuximab-treated
patients and has no predictive value for efficacy. Patients
with impaired renal function as indicated by serum
creatinine are more prone to develop hypocalcemia.
Therefore, patients with a serum creatinine in the high
normal range should be monitored for hypocalcemia when
treated with cetuximab. Hypomagnesemia is a common
event in cetuximab-treated patients. Data from clinical
trials not requiring a close follow-up of magnesium levels
probably underestimate the frequency of hypomagnese-
mia. Because of a greater magnesium waste in patients
receiving cetuximab in combination with platinum
derivatives, a higher awareness of hypomagnesemia is
recommended. If clinical symptoms appear, intravenous
magnesium administration and discontinuation of cetux-
imab are most efficient to restore magnesium levels.
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